~~<i id='3F16FF0D18'><strike id='3F16FF0D18'><tt id='3F16FF0D18'><pre id='3F16FF0D18'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

leisure time

author：leisure time 2025-09-28 02:30:48 - browse：95127

Blue nerve cell surrounded by red antibodies. -- health coverage from STAT — Adobe

Belgian drugmaker Argenx said Monday that its antibody treatment called Vyvgart significantly delayed the progression of an autoimmune nerve disorder that causes people to lose feeling and muscle strength in the arms and legs.

The positive outcome — a 61% reduction in the risk of relapse compared to a placebo — achieved the main goal of a Phase 3 clinical trial designed to demonstrate Vyvgart’s benefit for patients with chronic inflammatory demyelinating polyneuropathy, or CIDP.

“We hit the bullseye,” said Argenx CEO Tim Van Hauwermeiren.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Eli Lilly’s Mounjaro succeeds in second weight

hotspot

knowledge

hotspot

Wikipedia

hotspot

explore

AhearttransplantoperationattheClevelandClinic.AndreaYanak/APAnewmethodofhearttransplantationthatuses

WSS

What to expect as Trump is arraigned on his Jan 6. indictment

Infectious disease expert Jeanne Marrazzo assumes Fauci role

What to expect as Trump is arraigned on his Jan 6. indictment

Lawsuit alleges UnitedHealth Group unit illegally denied claims

NIH launches clinical trials and new research office for long Covid

Sage hopes for a blockbuster in antidepressant now before FDA

hotspot

leisure time

hotspot

Guidelines to prevent youth baseball injuries need more muscle

Biogen nominates mother of director’s child to replace him on board

FDA approval of Sarepta Duchenne genetic therapy gives me hope

What the airline industry can learn from medicine

Walensky prepares to leave CDC — and Congress — behind

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

Bright Health sells Medicare Advantage business to Molina

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

The high cost of giving birth even with insurance

Can medical device makers keep up in the race to treat obesity?

knowledge

‘Oppenheimer’ and the risks of AI in health care

Pence says 'crackpot lawyers' told Trump what he wanted to hear

No plane should take off without an EpiPen onboard

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

EQRx, failed developer of low

Micronoma's microbiome cancer diagnostic approach under fire

hotspot

Wikipedia

hotspot

explore